# Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs

> **NCT07384013** · NA · RECRUITING · sponsor: **Rambam Health Care Campus** · enrollment: 30 (estimated)

## Conditions studied

- Oncologic Diseases
- Coagulation Defect
- Pain Management

## Interventions

- **DRUG:** metamizole
- **DRUG:** metamizole

## Key facts

- **NCT ID:** NCT07384013
- **Lead sponsor:** Rambam Health Care Campus
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07384013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07384013, "Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07384013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*